KLOW (BPC-157 + TB-500 + KPV + GHK-Cu)

Compound Profile

KLOW (BPC-157 + TB-500 + KPV + GHK-Cu) is reviewed here for multi-compound formulation context.

Research Summary

Evidence Strength Very limited

Primary Evidence

Safety notices, literature searches, limited protocol data

Research Focus

Blend logic, Compatibility, Safety context

Mechanism

Target context: VEGFR2; G-Actin; MMP; Alpha-MSH

Long-Term Data

Limited, unclear, or affected by safety flags.

Current Consensus

Claims need extra caution because evidence is thin or safety flags apply.

Route(s) Subcutaneous

Typical dose 3.2mg

Dosing window Anytime

Receptor / target VEGFR2; G-Actin; MMP; Alpha-MSH

Properties Dopamine Buffer

Pre-mixed No

How KLOW (BPC-157 + TB-500 + KPV + GHK-Cu) works in the body

Protocols

Protocol logic check

Medical literature and study context

Independent evidence

Regulatory status: not approved multi compound blend component warnings

Storage

No approved-label storage guidance was identified for this entry. Use conservative sterile handling and see the general storage guidance in the FAQ.

Contraindications & cautions

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

• Active cancer: BPC-157's VEGFR2-mediated angiogenic activity and GHK-Cu's comprehensive pro-growth gene program upregulation are absolutely contraindicated in active malignancy for the same reasons as GLOW; KPV's MC receptor-mediated anti-inflammatory activity in the tumor microenvironment is an additional consideration since tumor-associated inflammation suppression could theoretically reduce immune surveillance of the tumor.
• Zinc deficiency: GHK-Cu copper competition with zinc absorption applies identically to KLOW as to GLOW; zinc status must be confirmed and repleted before initiating KLOW; concurrent zinc supplementation (15-30mg/day) is required throughout all KLOW cycles.
• Wilson's disease: copper metabolism disorder; GHK-Cu copper delivery is absolutely contraindicated.
• Active autoimmune disease in acute flare: KPV's MC receptor-mediated anti-inflammatory activity produces immune modulation; in some autoimmune conditions, the NF-κB suppression is beneficial (IBD, psoriasis, skin inflammation); in others (systemic lupus, vasculitis, severe rheumatoid arthritis flare), the interaction between KPV's immune modulation and the existing dysregulated immune response requires medical supervision and monitoring.
• Concurrent immunosuppressive therapy (calcineurin inhibitors, biologics for autoimmune disease, post-transplant immunosuppression): KPV's MC receptor-mediated immune regulation adds an exogenous immunomodulatory layer to subjects already on potent immunosuppressive regimens; the combined immune system activity has not been characterized.
• Known hypersensitivity to BPC-157, TB-500, KPV (Lys-Pro-Val), GHK-Cu, or formulation excipients.
• Severe hepatic impairment: copper processing limitation applies identically to KLOW as GLOW.
• Pregnancy: the combined angiogenic, immune-modulatory (KPV), and copper-delivering activity of KLOW has not been evaluated during pregnancy.
• History of copper toxicity: previous copper sensitivity contraindicates the GHK-Cu component.
• Active infectious disease requiring antimicrobial management: KPV's NF-κB suppression and pro-inflammatory cytokine reduction could modestly attenuate the acute-phase inflammatory response that is part of the innate immune defense against active infection; KLOW is appropriate for post-infectious repair and maintenance and should not be used during an active systemic infection.

Possible side effects

Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions that still need confirmation against medical literature. Use the medical sources below to verify details.

• Injection site redness and welting: more pronounced than GLOW in some subjects; the addition of KPV adds a fourth peptide to the injection bolus and KPV's MC1R activation in local skin can produce mild cutaneous vasodilation at the injection site; typically resolves within 1-2 hours.
• Mild fatigue: attributable to the BPC-157/TB-500 dopaminergic modulation component; similar in character and duration to GLOW; typically mild and lasting 1-3 hours post-injection.
• Zinc depletion: the same critical monitoring parameter as GLOW; mandatory zinc supplementation throughout all KLOW cycles.
• Mild copper accumulation risk: identical to GLOW; the 5-days-on protocol and cycle limits mitigate this risk at standard doses.
• Mild pigmentary changes (uncommon): KPV as an alpha-MSH receptor agonist has very modest melanocyte-stimulating activity compared to full-length alpha-MSH or Melanotan; mild, transient, and far less pronounced than Melanotan-1 or -2; not expected at the 400mcg/day KPV doses in KLOW but represents a theoretical consideration for subjects with existing pigmentation conditions.
• Transient blood pressure changes: KPV's vasodilatory activity at MC receptors in vascular endothelium may produce mild transient blood pressure fluctuations in the first days of a cycle; typically self-limiting.
• Anhedonia (rare): same BPC-157 dopaminergic mechanism as GLOW; rare; typically transient.
• Mild nausea in first cycle days: occasionally reported with the four-peptide combination; mechanism may involve KPV's area postrema MC receptor interaction; typically resolves within the first week.
• Elevated liver enzymes (ALT/AST): same hepatic copper processing consideration as GLOW; monitor in subjects with pre-existing liver conditions.

Compatibility

The relationships below are heuristic compatibility notes and were not independently verified. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.

Reported synergistic:

Reported contraindicated combinations:

Sources

• FDA drug/regulatory guidance
• FDA bulk-substance safety risk page
• PubMed literature search: KLOW (BPC-157 TB-500 KPV GHK-Cu)
• ClinicalTrials.gov study records: KLOW (BPC-157 TB-500 KPV GHK-Cu)
• NIH Office of Dietary Supplements fact sheet
• PubMed literature search: BPC-157
• PubMed literature search: thymosin beta 4
• PubMed literature search: KPV peptide
• PubMed literature search: GHK-Cu